Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$435M |
| 2 |
Amazon
AMZN
|
+$334M |
| 3 |
Moderna
MRNA
|
+$53.9M |
| 4 |
Linde
LIN
|
+$44.2M |
| 5 |
DTE Energy
DTE
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$63.6M |
| 2 |
Comcast
CMCSA
|
+$39.7M |
| 3 |
Evergy
EVRG
|
+$38.5M |
| 4 |
Public Service Enterprise Group
PEG
|
+$38.4M |
| 5 |
Bio-Techne
TECH
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 31.51% |
| 2 | Technology | 15.37% |
| 3 | Consumer Discretionary | 10.36% |
| 4 | Financials | 7.14% |
| 5 | Industrials | 6.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1501
Merchants Bancorp
MBIN
$2.45B
| $454K | 0.01% |
17,345
+4,595
| +36% | +$127K |
|
1502
Viking Therapeutics
VKTX
$3.95B
| $453K | 0.01% |
75,640
+16,357
| +28% | +$97.1K |
|
1503
Marcus & Millichap
MMI
$1.2B
| $452K | 0.01% |
11,618
-7,292
| -39% | -$274K |
|
1504
Patria Investments
PAX
$1.88B
| $452K | 0.01% |
25,675
-68,660
| -73% | -$1.1M |
|
1505
Home BancShares
HOMB
$5.94B
| $450K | 0.01% |
+18,215
| New | +$492K |
|
1506
Melco Resorts & Entertainment
MLCO
$1.97B
| $450K | 0.01% |
27,154
-89,143
| -77% | -$1.62M |
|
1507
Odyssey Marine Exploration
OMEX
$52.9M
| $450K | 0.01% |
70,791
-9
| -0% | -$59 |
|
|
TRUE
1508
DELISTED
TrueCar
TRUE
| $450K | 0.01% |
79,682
-47,504
| -37% | -$239K |
|
1509
Energy Fuels
UUUU
$3.93B
| $450K | 0.01% |
74,310
+49,677
| +202% | +$305K |
|
|
RAAS
1510
DELISTED
Cloopen Group Holding Limited American Depositary Shares (each representing six (6) Class A Ordinary Shares)
RAAS
| $450K | 0.01% |
17,673
+2,600
| +17% | +$77.3K |
|
|
CTAQU
1511
DELISTED
Carney Technology Acquisition Corp. II Units
CTAQU
| $450K | 0.01% |
45,000
| – | – |
|
1512
Merit Medical Systems
MMSI
$5.35B
| $449K | 0.01% |
+6,944
| New | +$429K |
|
1513
New Jersey Resources
NJR
$5.46B
| $449K | 0.01% |
11,351
-66,365
| -85% | -$2.8M |
|
1514
Energy Recovery
ERII
$403M
| $448K | 0.01% |
19,686
-16,263
| -45% | -$321K |
|
1515
Wave Life Sciences
WVE
$1.02B
| $447K | ﹤0.01% |
+67,178
| New | +$439K |
|
1516
Cohen & Steers
CNS
$4.25B
| $446K | ﹤0.01% |
5,431
-6,173
| -53% | -$445K |
|
1517
SiTime
SITM
$18B
| $445K | ﹤0.01% |
3,512
-15,479
| -82% | -$1.58M |
|
1518
York Water
YORW
$547M
| $445K | ﹤0.01% |
+9,817
| New | +$487K |
|
1519
Caledonia Mining Corp
CMCL
$493M
| $444K | ﹤0.01% |
+36,701
| New | +$516K |
|
1520
PubMatic
PUBM
$745M
| $444K | ﹤0.01% |
+11,357
| New | +$473K |
|
1521
Titan Machinery
TITN
$429M
| $444K | ﹤0.01% |
+14,348
| New | +$402K |
|
|
IVAC
1522
DELISTED
Intevac Inc
IVAC
| $444K | ﹤0.01% |
+65,937
| New | +$429K |
|
1523
Vericel Corp
VCEL
$2.11B
| $443K | ﹤0.01% |
+8,447
| New | +$481K |
|
1524
Applied Optoelectronics
AAOI
$9.62B
| $442K | ﹤0.01% |
+52,210
| New | +$425K |
|
1525
Quanta Services
PWR
$93.5B
| $442K | ﹤0.01% |
4,875
-50,004
| -91% | -$4.7M |
|
Similar funds
Michael Gelband's Q2 2021 Portfolio in Review
As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Michael Gelband deployed $1.22B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.
By sector, the portfolio is most concentrated in Miscellaneous at 32% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.
- Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
- Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
- Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
- Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
- Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
- Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
- Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.